Dietary compound ellagic acid alleviates skin wrinkle and inflammation induced by UV-B irradiation.
Ellagic acid, a polyphenol compound present in berries and pomegranate, has received attention as an agent that may have potential bioactivities preventing chronic diseases. This study examined photoprotective effects of ellagic acid on collagen breakdown and inflammatory responses in UV (ultraviolet)-B irradiated human skin cells and hairless mice. Ellagic acid attenuated the UV-B-induced toxicity of HaCaT keratinocytes and human dermal fibroblasts. Non-toxic ellagic acid markedly prevented collagen degradation by blocking matrix metalloproteinase production in UV-B-exposed fibroblasts. Anti-wrinkle activity of ellagic acid was further investigated in hairless mice exposed to UV-B, in which it attenuated UV-B-triggered skin wrinkle formation and epidermal thickening. Topical application of 10 micromol/l ellagic acid diminished production of pro-inflammatory cytokines IL-1beta and IL-6, and blocked infiltration of inflammatory macrophages in the integuments of SKH-1 hairless mice exposed to UV-B for 8 weeks. In addition, this compound mitigated inflammatory intracellular cell adhesion molecule-1 expression in UV-B-irradiated keratinocytes and photoaged mouse epidermis. These results demonstrate that ellagic acid prevented collagen destruction and inflammatory responses caused by UV-B. Therefore, dietary and pharmacological interventions with berries rich in ellagic acid may be promising treatment strategies interrupting skin wrinkle and inflammation associated with chronic UV exposure leading to photoageing.
Bae
Ji-Young
JY
Department of Food and Nutrition, Hallym University, Chuncheon, Korea.
Choi
Jung-Suk
JS
Kang
Sang-Wook
SW
Lee
Yong-Jin
YJ
Park
Jinseu
J
Kang
Young-Hee
YH
D000818:Animals; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D002478:Cells, Cultured; D003094:Collagen / Q000378:metabolism; D003872:Dermatitis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004610:Ellagic Acid / Q000494:pharmacology* / Q000627:therapeutic use*; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D015603:Keratinocytes / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D008297:Male; D020782:Matrix Metalloproteinases / Q000378:metabolism; D051379:Mice; D008812:Mice, Hairless; D023421:Models, Animal; D015595:Skin Aging / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects; D016896:Treatment Outcome; D014466:Ultraviolet Rays / Q000009:adverse effects*
D053583:Interleukin-1beta; D015850:Interleukin-6; D004610:Ellagic Acid; D003094:Collagen; D020782:Matrix Metalloproteinases